Tissue Distribution and Excretion of 125I-lidamycin in Mice and Rats

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2005 Jun 2

PMID 15929183

Citations 3

Authors

You-Ping Liu

Quan-Sheng Li

Yu-Rong Huang

Chang-Xiao Liu

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate the tissue distribution, urinary and fecal excretions of (125)I-lidamycin ((125)I-C-1027) in mice and its biliary excretion in rats.

Methods: The total radioactivity assay (RA method) and the radioactivity assay after precipitation with 200 mL/L trichloroacetic acid (TCA-RA method) were used to determine the tissue distribution, and the urinary and fecal excretions of (125)I-C-1027 in mice and its biliary excretion in rats.

Results: Tissue concentrations reached the peak at the fifth minute after administration of (125)I-C-1027 to mice. The highest concentration was in kidney, and the lowest in brain at all test-time points. The organs of the concentrations of (125)I-C-1027 from high to low were kidney, lung, liver, stomach, spleen, uterus, ovary, intestine, muscle, heart, testis, fat, and brain in mice. The accumulative excretion amounts of 0-24 h, and 0-96 h after administration of (125)I-C-1027 were 68.36 and 71.64% in urine, and 2.60 and 3.21% in feces of mice, respectively, and the accumulative excretion amount of 0-24 h was 3.57% in bile in rats.

Conclusion: Our results reflect the characteristics of the tissue distribution, urinary and fecal excretions of (125)I-C-1027 in mice and the biliary excretion of (125)I-C-1027 and its metabolites in rats, and indicate that (125)I-C-1027 and its metabolites are mainly distributed in kidney, and excreted in urine.

Citing Articles

Interventional therapy for human breast cancer in nude mice with 131I gelatin microspheres (¹³¹I-GMSs) following intratumoral injection.

Li C, Chi J, Ma Y, Li J, Xia C, Li L Radiat Oncol. 2014; 9:144.

PMID: 24958442 PMC: 4083354. DOI: 10.1186/1748-717X-9-144.

Direct in vivo injection of 131I-GMS and its distribution and excretion in rabbit.

Ma Y, Wan Y, Luo D, Duan L, Li L, Xia C World J Gastroenterol. 2010; 16(17):2120-8.

PMID: 20440852 PMC: 2864837. DOI: 10.3748/wjg.v16.i17.2120.

Anticancer activity of natural and synthetic acetylenic lipids.

Dembitsky V Lipids. 2006; 41(10):883-924.

PMID: 17180879 DOI: 10.1007/s11745-006-5044-3.

References

Wang Z, He Q, Liang Y, Wang D, Li Y, Li D . Non-caspase-mediated apoptosis contributes to the potent cytotoxicity of the enediyne antibiotic lidamycin toward human tumor cells. Biochem Pharmacol. 2003; 65(11):1767-75. DOI: 10.1016/s0006-2952(03)00117-5. View

Zhou C, Xu L, Jiang M, Zhen Y . [A monoclonal antibody directed against an enediyne antitumor antibiotic and its preliminary application]. Yao Xue Xue Bao. 1997; 32(1):28-32. View

Cui D, Wang Z, Li D . [Effect of lidamycin on the expression of genes involved in invasion regulation in HCT-8 human colon cancer cells]. Yao Xue Xue Bao. 2003; 36(4):246-9. View

Tang Z, Liu X, Xu L, Shan C, Song Q . Pharmacokinetics and tissue distribution of human recombinant interleukin-2 in mice. Zhongguo Yao Li Xue Bao. 1994; 15(1):51-6. View

He Q, Jiang B, Li D, Zhen Y . [Effects of lidamycin on apoptotic gene expressions and cytoskeleton in human hepatoma bel-7402 cells]. Ai Zheng. 2002; 21(4):351-5. View

Pannell R, Gurewich V . Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Blood. 1986; 67(5):1215-23. View

Otani T, Minami Y, Marunaka T, Zhang R, Xie M . A new macromolecular antitumor antibiotic, C-1027. II. Isolation and physico-chemical properties. J Antibiot (Tokyo). 1988; 41(11):1580-5. DOI: 10.7164/antibiotics.41.1580. View

Liu J, Kuo S, Yin X, Beerman T, Melendy T . DNA damage by the enediyne C-1027 results in the inhibition of DNA replication by loss of replication protein A function and activation of DNA-dependent protein kinase. Biochemistry. 2001; 40(48):14661-8. DOI: 10.1021/bi015680c. View

Hu J, Xue Y, Xie M, Zhang R, Otani T, Minami Y . A new macromolecular antitumor antibiotic, C-1027. I. Discovery, taxonomy of producing organism, fermentation and biological activity. J Antibiot (Tokyo). 1988; 41(11):1575-9. DOI: 10.7164/antibiotics.41.1575. View

10.

Totsuka R, Aizawa Y, Uesugi M, Okuno Y, Matsumoto T, Sugiura Y . RNA cleavage by C-1027 chromophore, an enediyne antitumor antibiotic: high selectivity to an anticodon arm. Biochem Biophys Res Commun. 1995; 208(1):168-73. DOI: 10.1006/bbrc.1995.1319. View

11.

Shah V, Midha K, Dighe S, McGilveray I, Skelly J, Yacobi A . Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet. 1991; 16(4):249-55. DOI: 10.1007/BF03189968. View

12.

Zhen Y, Ming X, Yu B, Otani T, Saito H, Yamada Y . A new macromolecular antitumor antibiotic, C-1027. III. Antitumor activity. J Antibiot (Tokyo). 1989; 42(8):1294-8. DOI: 10.7164/antibiotics.42.1294. View

13.

Otani T . Conformation studies on and assessment by spectral analysis of the protein-chromophore interaction of the macromolecular antitumor antibiotic C-1027. J Antibiot (Tokyo). 1993; 46(5):791-802. DOI: 10.7164/antibiotics.46.791. View

14.

Shao R, Zhen Y . [Relationship between the molecular composition of C1027, a new macromolecular antibiotic with enediyne chromophore, and its antitumor activity]. Yao Xue Xue Bao. 1995; 30(5):336-42. View

15.

Matsumoto T, Okuno Y, Sugiura Y . Specific interaction between a novel enediyne chromophore and apoprotein in macromolecular antitumor antibiotic C-1027. Biochem Biophys Res Commun. 1993; 195(2):659-66. DOI: 10.1006/bbrc.1993.2096. View

16.

Xu Y, Li D, Zhen Y . Mode of action of C-1027, a new macromolecular antitumor antibiotic with highly potent cytotoxicity, on human hepatoma BEL-7402 cells. Cancer Chemother Pharmacol. 1990; 27(1):41-6. DOI: 10.1007/BF00689274. View